0001104659-23-075792.txt : 20230628 0001104659-23-075792.hdr.sgml : 20230628 20230628160520 ACCESSION NUMBER: 0001104659-23-075792 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230628 DATE AS OF CHANGE: 20230628 EFFECTIVENESS DATE: 20230628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: First Wave BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-485434 FILM NUMBER: 231052124 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 D 1 primary_doc.xml X0708 D LIVE 0001604191 First Wave BioPharma, Inc. 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 561-589-7020 DELAWARE None AzurRx BioPharma, Inc. BioPharma d'Azur, Inc. Corporation true James Sapirstein 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Executive Officer Director Sarah Romano 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Executive Officer Terry Coelho 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Director David Hoffman 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Director Edward Borkowski 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Director Alastair Riddell 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Director Charles Casamento 777 YAMATO ROAD SUITE 502 BOCA RATON FL FLORIDA 33431 Director Biotechnology Decline to Disclose 06b false 2023-06-13 false true false 0 Roth Capital Partners, LLC 15407 None None 888 SAN CLEMENTE SUITE 400 NEWPORT BEACH CA CALIFORNIA 92660 All States false 431083 431083 0 false 1 150000 0 0 true Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3. false First Wave BioPharma, Inc. /s/ James Sapirstein James Sapirstein President and CEO 2023-06-28